Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GALD.SW
- Price
- 155.30
- Stock movement up
- +5.60 (3.74%)
- Company name
- Galderma Group N
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 36.47B
- Ent value
- 41.16B
- Price/Sales
- 6.05
- Price/Book
- 4.72
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 98.56
- Forward P/E
- 49.15
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-25
DIVIDENDS
GALD.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 98.56 |
| Price to OCF | 38.79 |
| Price to FCF | 44.39 |
| Price to EBITDA | 27.21 |
| EV to EBITDA | 30.71 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.05 |
| Price to Book | 4.72 |
| EV to Sales | 6.83 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 234.82M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 3.16 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 458.00M |
| Net receivables | 931.00M |
| Total current assets | 1.91B |
| Goodwill | 5.13B |
| Intangible assets | 4.75B |
| Property, plant and equipment | 0.00 |
| Total assets | 12.88B |
| Accounts payable | 762.00M |
| Short/Current long term debt | 2.85B |
| Total current liabilities | 1.75B |
| Total liabilities | 5.15B |
| Shareholder's equity | 7.73B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 154.00 |
| Daily high | 155.50 |
| Daily low | 151.40 |
| Daily Volume | 409K |
| All-time high | 155.30 |
| 1y analyst estimate | 150.31 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 25 Apr 2025 |
| Next earnings date | 12 Feb 2026 |
Downside potential
Loading...
Downside potential data
| GALD.SW | S&P500 | |
| Current price drop from All-time high | -2.35% | -2.71% |
| Highest price drop | -7.97% | -19.00% |
| Date of highest drop | 22 Oct 2025 | 8 Apr 2025 |
| Avg drop from high | -2.75% | -2.73% |
| Avg time to new high | 3 days | 6 days |
| Max time to new high | 17 days | 89 days |
COMPANY DETAILS
Marketcap
36.47B
Marketcap category
Large-cap
Description
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Galderma Group’s consensus analyst price target has edged up from CHF 149.91 to CHF 150.37, reflecting analysts’ renewed optimism for the stock’s prospects. The modest adjustment follows active engage...
November 17, 2025
ZUG, Switzerland, November 17, 2025--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline a...
November 17, 2025
ZUG, Switzerland, November 05, 2025--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Rest...
November 5, 2025
Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce the completion of the placement of 20 million shares in Galderma Group AG (SIX: GALD) (the...
October 30, 2025
ZUG, Switzerland, October 23, 2025--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record ...
October 23, 2025
Key Insights The projected fair value for Galderma Group is CHF240 based on 2 Stage Free Cash Flow to Equity Current...
October 2, 2025
ZUG, Switzerland, September 24, 2025--Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC)...
September 24, 2025
ZUG, Switzerland, September 18, 2025--Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Act...
September 18, 2025
ZUG, Switzerland, September 17, 2025--Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles an...
September 17, 2025
ZUG, Switzerland, September 11, 2025--Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34th European Academy of Dermatology and V...
September 11, 2025
Next page